Results 161 to 170 of about 214,611 (264)

Polymer–lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells

, 2017
Jun Li,1,* Wenqing Xu,2,* Xiaoli Yuan,3,* Huaiwen Chen,3 Hao Song,1,4 Bingquan Wang,5 Jun Han5 1College of Pharmacy, Liaocheng University, Liaocheng, Shandong, 2Railway Police College, Zhengzhou, 3Department of Cadre Health Care, Nanjing General ...
Xu WQ, Yuan XL, Li J, Chen HW, Han J, Song H, Wang BQ   +6 more
core  

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

BMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim, Marwa Ahmed El‐Naka, Wedad M. Nageeb, Atta Ullah Khan, Noura M. Seleem, Aliaa Abdelghafar, Doaa Zamel, Yang Liu, Qigai He, Wentao Li   +9 more
wiley   +1 more source

Optimizing the ER Cutoff in HER2-Positive Breast Cancer: ER ≥ 50% Predicts Low pCR Rates and Resistance to Antibody-Drug Conjugates in the Neoadjuvant Setting. [PDF]

Cancer Med
Du T, Lin M, Liang G, Wang Y, Wu H, Zhao Z, Sun L, Tang J.   +7 more
europepmc   +1 more source

Unfavorable Prognostic Impact of HER2 2+/FISH-Negativity in Older Patients with HER2-Negative and High-Risk Breast Cancer [PDF]

Hao Wang,1 Miao Yu,1 Meihua Chen,2 Hui Li,1 Shiwei Liu1 1Department of Breast, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and ...
Li H, Yu M, Chen M, Wang H, Liu S
core  

Multivalent RNA‐Cleaving Agents on a Cubic Octameric Silsesquioxane Core

Chemistry – A European Journal, EarlyView.
RNA‐cleaving agents on a cubic octameric silsesquioxane core were synthesized and characterized. Several catalytic systems of these structures were screened using hexaribonucleotide models. The best systems were then further used to study their catalytic efficiency in cleaving a HER2 mRNA model sequence. The induced cleavage sites were also determined.
Hanni Haapsaari, Iris Tuomi, Pasi Virta
wiley   +1 more source

The impact of intratumor heterogeneity on outcome and resistance to therapy in primary breast cancer: a systematic review. [PDF]

Med Oncol
Dianati A, Dekker A, Wesselius A, Wee L.
europepmc   +1 more source

Characterization of Lysosomal Hydrolases and Transporters and Their Age‐Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Lysosomes play a key role in the accumulation, catabolism, and transport of endogenous and exogenous metabolites and proteins and are involved in drug metabolism and prodrug activation. However, the protein abundance and interindividual variability of lysosomal drug‐metabolizing enzymes and transporters (DMETs) remain underexplored.
Darshak Gadara, Dilip Kumar Singh, Sandhya Subash, Guihua Yue, Deepak Ahire, Chris Bohl, Maciej Czerwinski, Stephanie Helmstetter, Scott Heyward, Robert S. Jones, Cyrus Khojasteh, Ryota Kikuchi, Priyanka Kulkarni, Bin Ma, Bernard Murray, Chris Seib, Bill Smith, David M. Stresser, Mitchell E. Taub, Ting Wang, Bhagwat Prasad   +20 more
wiley   +1 more source

Breast cancer immunogenicity as a spectrum: evolving concepts and therapeutic implications. [PDF]

J Clin Invest
Kay J, Dixon-Douglas JR, Harris MA, van Geelen CT, Loi S.   +4 more
europepmc   +1 more source

Maternal and Neonatal Complications Associated with Breast Cancer Systemic Treatments—A VigiBase Disproportionality Analysis Study

Clinical Pharmacology &Therapeutics, EarlyView.
Pregnancy‐associated breast cancer (PrBC) presents therapeutic challenges. Understanding maternal–fetal safety of systemic anticancer therapies is critical. We performed a case/non‐case disproportionality analysis using the WHO global pharmacovigilance database up to January 2024, to evaluate maternal–fetal outcomes associated with breast cancer (BC ...
Rayan Kabirian, Floriane Jochum, Elise Dumas, Florence Coussy, Kevin Bihan, Bénédicte Lebrun‐Vignes, Barbara Pistilli, Marc‐Antoine Benderra, Lise Selleret, Laurent Chouchana, Fabien Reyal, Anne‐Sophie Hamy, Paul Gougis   +12 more
wiley   +1 more source

Biography as the Missing Variable in Drug Development: A Case for Bio‐Biographical Mechanistic Profiling

Clinical Pharmacology &Therapeutics, EarlyView.
Most clinical trial failures reflect unmeasured biological heterogeneity. Biography — chronic stress, adversity, trauma, and social isolation—is a neglected source of that heterogeneity, operating through the same molecular pathways drugs engage.
Ralph I. Horwitz
wiley   +1 more source